Skip to main content
SpringerLink
Log in

Treatment of the primary tumor in metastatic prostate cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

The cornerstone of treatment for metastatic prostate cancer patients has been conventional androgen deprivation therapy, with additional systemic therapy initiated only after castration resistance, and local therapy reserved for palliation. Compelling results from modern trials challenge this paradigm, arguing for initiating escalated hormone therapy and/or chemotherapy during the castration-sensitive disease state for many patients. Furthermore, modern radiotherapy techniques allow for local control of disease with low risk of toxicity. Finally, new PET probes with enhanced sensitivity and accuracy are likely to become a part of routine staging and will lead to an increased incidence of patients with metastatic disease at presentation, with a shift toward identification of patients with limited metastatic disease. As such, the landscape is primed for investigations aimed to explore the role of primary tumor therapy for patients with metastatic prostate cancer. We review the existing data evaluating primary tumor therapy for patients with metastatic prostate cancer and describe ongoing clinical trials testing the hypothesis that primary tumor therapy may benefit patients with metastatic prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mohler JL, Lee RJ, Antonarakis ES et al (2018) National Comprehensive Cancer Network. Prostate Cancer (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 16 July 2018

  2. Huggins C, Hodges CV (2002) Studies on prostatic cancer. J Urol 167:948–951. https://doi.org/10.1016/S0022-5347(02)80307-X

    Article  CAS  PubMed  Google Scholar 

  3. Schally AV, Arimura A, Kastin AJ et al (1971) Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 173:1036–1038

    Article  CAS  PubMed  Google Scholar 

  4. James ND, Spears MR, Clarke NW et al (2015) Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 67:1028–1038. https://doi.org/10.1016/j.eururo.2014.09.032

    Article  PubMed  Google Scholar 

  5. Nguyen PL, Alibhai SMH, Basaria S et al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67:825–836. https://doi.org/10.1016/j.eururo.2014.07.010

    Article  CAS  PubMed  Google Scholar 

  6. Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360. https://doi.org/10.1056/NEJMoa1704174

    Article  CAS  PubMed  Google Scholar 

  7. James ND, de Bono JS, Spears MR et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351. https://doi.org/10.1056/NEJMoa1702900

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kim M-Y, Oskarsson T, Acharyya S et al (2009) Tumor self-seeding by circulating cancer cells. Cell 139:1315–1326. https://doi.org/10.1016/j.cell.2009.11.025

    Article  PubMed  PubMed Central  Google Scholar 

  9. Gundem G, Van Loo P, Kremeyer B et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353–357. https://doi.org/10.1038/nature14347

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kaplan RN, Rafii S, Lyden D (2006) Preparing the “soil”: the premetastatic niche. Cancer Res 66:11089–11093. https://doi.org/10.1158/0008-5472.CAN-06-2407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cai C, Balk SP (2011) Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 18:R175–R182. https://doi.org/10.1530/ERC-10-0339

    Article  CAS  PubMed  Google Scholar 

  12. Heidenreich A, Pfister D, Porres D (2015) Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 193:832–838. https://doi.org/10.1016/j.juro.2014.09.089

    Article  PubMed  Google Scholar 

  13. Won ACM, Gurney H, Marx G et al (2013) Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 112:E250–E255. https://doi.org/10.1111/bju.12169

    Article  PubMed  Google Scholar 

  14. Steinberg GD, Epstein JI, Piantadosi S, Walsh PC (1990) Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 144:1425–1432

    Article  CAS  PubMed  Google Scholar 

  15. Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659. https://doi.org/10.1056/NEJMoa003013

    Article  CAS  PubMed  Google Scholar 

  16. Mickisch GH, Garin A, van Poppel H et al (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970

    Article  CAS  PubMed  Google Scholar 

  17. Méjean A, Ravaud A, Thezenas S et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379:417–427. https://doi.org/10.1056/NEJMoa1803675

    Article  PubMed  Google Scholar 

  18. Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259. https://doi.org/10.1200/JCO.2002.20.5.1248

    Article  PubMed  Google Scholar 

  19. Fader AN, Rose PG (2007) Role of surgery in ovarian carcinoma. J Clin Oncol 25:2873–2883. https://doi.org/10.1200/JCO.2007.11.0932

    Article  PubMed  Google Scholar 

  20. du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115:1234–1244. https://doi.org/10.1002/cncr.24149

    Article  CAS  PubMed  Google Scholar 

  21. Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766

    Article  PubMed  PubMed Central  Google Scholar 

  22. Pawlik TM, Scoggins CR, Zorzi D et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241: 715–722:discussion 722–724

    Google Scholar 

  23. Pitroda SP, Khodarev NN, Huang L et al (2018) Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. https://doi.org/10.1038/s41467-018-04278-6

    Article  PubMed  PubMed Central  Google Scholar 

  24. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. PubMed NCBI. https://www.ncbi.nlm.nih.gov/pubmed/27380959. Accessed 2 Oct 2018

  25. Harris E, Barry M, Kell MR (2013) Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol 20:2828–2834. https://doi.org/10.1245/s10434-013-2998-2

    Article  PubMed  Google Scholar 

  26. Badwe R, Hawaldar R, Nair N et al (2015) Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol 16:1380–1388. https://doi.org/10.1016/S1470-2045(15)00135-7

    Article  PubMed  Google Scholar 

  27. DallEra MA, Lo MJ, Chen J et al (2018) Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer: local therapy in advanced prostate cancer. Cancer 124:1921–1928. https://doi.org/10.1002/cncr.31285

    Article  CAS  Google Scholar 

  28. Kelly SP, Anderson WF, Rosenberg PS, Cook MB (2018) Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus 4:121–127. https://doi.org/10.1016/j.euf.2017.10.014

    Article  PubMed  Google Scholar 

  29. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM (2016) Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis 19:395–397. https://doi.org/10.1038/pcan.2016.30

    Article  CAS  PubMed  Google Scholar 

  30. Calais J, Cao M, Nickols NG (2018) The utility of PET/CT in the planning of external radiation therapy for prostate cancer. J Nucl Med 59:557–567. https://doi.org/10.2967/jnumed.117.196444

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Widmark A, Klepp O, Solberg A et al (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373:8

    Article  Google Scholar 

  32. Warde P, Mason M, Ding K et al (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378:2104–2111. https://doi.org/10.1016/S0140-6736(11)61095-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. James ND, Spears MR, Clarke NW et al (2014) Impact of node status and radiotherapy on failure-free survival in patients with newly-diagnosed non-metastatic prostate cancer: data from > 690 patients in the control arm of the STAMPEDE trial. Int J Radiat Oncol Biol Phys 90:S13. https://doi.org/10.1016/j.ijrobp.2014.05.095

    Article  Google Scholar 

  34. Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65:1058–1066. https://doi.org/10.1016/j.eururo.2013.11.012

    Article  PubMed  Google Scholar 

  35. Antwi S, Everson TM (2014) Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol 38:435–441. https://doi.org/10.1016/j.canep.2014.04.002

    Article  PubMed  Google Scholar 

  36. Satkunasivam R, Kim AE, Desai M et al (2015) Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol 194:378–385. https://doi.org/10.1016/j.juro.2015.02.084

    Article  PubMed  PubMed Central  Google Scholar 

  37. Parikh RR, Byun J, Goyal S, Kim IY (2017) Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate 77:559–572. https://doi.org/10.1002/pros.23294

    Article  PubMed  Google Scholar 

  38. Löppenberg B, Dalela D, Karabon P et al (2017) The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur Urol 72:14–19. https://doi.org/10.1016/j.eururo.2016.04.031

    Article  PubMed  Google Scholar 

  39. Leyh-Bannurah S-R, Gazdovich S, Budäus L et al (2017) Local therapy improves survival in metastatic prostate cancer. Eur Urol 72:118–124. https://doi.org/10.1016/j.eururo.2017.03.020

    Article  PubMed  Google Scholar 

  40. Steuber T, Berg KD, Røder MA et al (2017) Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study. Eur Urol Focus 3:646–649. https://doi.org/10.1016/j.euf.2017.06.016

    Article  PubMed  Google Scholar 

  41. Cho Y, Chang JS, Rha KH et al (2016) Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis? PLoS One 11:e0147191. https://doi.org/10.1371/journal.pone.0147191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Rusthoven CG, Jones BL, Flaig TW et al (2016) Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol 34:2835–2842. https://doi.org/10.1200/JCO.2016.67.4788

    Article  CAS  PubMed  Google Scholar 

  43. Gratzke C, Engel J, Stief CG (2014) Role of radical prostatectomy in metastatic prostate cancer: data from the munich cancer registry. Eur Urol 66:602–603. https://doi.org/10.1016/j.eururo.2014.04.009

    Article  PubMed  Google Scholar 

  44. Boevé LMS, Hulshof MCCM, Vis AN et al (2018) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. https://doi.org/10.1016/j.eururo.2018.09.008

    Article  PubMed  Google Scholar 

  45. Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. https://doi.org/10.1016/S0140-6736(18)32486-3

    Article  PubMed  PubMed Central  Google Scholar 

  46. Sweeney CJ, Chen Y-H, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746. https://doi.org/10.1056/NEJMoa1503747

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446–453. https://doi.org/10.1200/JCO.2017.75.4853

    Article  CAS  PubMed  Google Scholar 

  48. O’Shaughnessy MJ, McBride SM, Vargas HA et al (2017) A Pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer. Urology 102:164–172. https://doi.org/10.1016/j.urology.2016.10.044

    Article  PubMed  Google Scholar 

  49. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10. https://doi.org/10.1200/JCO.1995.13.1.8

    Article  CAS  PubMed  Google Scholar 

  50. Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195–202

    Article  CAS  PubMed  Google Scholar 

  51. Singh D, Yi WS, Brasacchio RA et al (2004) Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 58:3–10. https://doi.org/10.1016/S0360-3016(03)01442-1

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, UCLA, Los Angeles, CA, USA

    Ye Yuan, Amar U. Kishan & Nicholas G. Nickols

  2. Department of Radiation Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA

    Nicholas G. Nickols

Authors
  1. Ye Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amar U. Kishan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicholas G. Nickols
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YY: data collection, data analysis, manuscript writing. AUK: data collection, data analysis, manuscript writing. NGN: data collection, data analysis, manuscript writing.

Corresponding author

Correspondence to Nicholas G. Nickols.

Ethics declarations

Conflict of interest

The authors have no potential conflicts of interest to disclose. As this is a review article, there was no research involving human participants or animals, nor informed consent needed.

Additional information

Ye Yuan is the first author.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yuan, Y., Kishan, A.U. & Nickols, N.G. Treatment of the primary tumor in metastatic prostate cancer. World J Urol 37, 2597–2606 (2019). https://doi.org/10.1007/s00345-018-2552-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-018-2552-8

Keywords

Search

Navigation